{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-066553","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.772699+00:00","generated_at":"2026-06-01T07:22:58.218642+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ultragenyx Phase 3 DTX401 gene therapy meets primary endpoint in GSDIa","bullets":["DTX401 reduced daily cornstarch intake by 41.3% vs 10.3% for placebo at Week 48 (p<0.0001).","68% of DTX401 patients achieved ≥30% reduction; 37% achieved ≥50% reduction.","Secondary endpoint met: 1.1 fewer cornstarch doses/day vs 0.2 for placebo (p=0.0011).","Safety profile acceptable; no dorsal root ganglion toxicity or thrombotic microangiopathy observed.","Company plans to discuss results with regulators and submit marketing application in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-066553","json":"https://secwatch.observer/filing/0000950170-24-066553.json","markdown":"https://secwatch.observer/filing/0000950170-24-066553.md","text":"https://secwatch.observer/filing/0000950170-24-066553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024066553/0000950170-24-066553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024066553/rare-20240530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:22:58.218642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}